Neutralization of infectivity of porcine circovirus type 2 (PCV2) by capsid-binding 2'F-RNA aptamers

• Published in: Antiviral research Vol. 88; no. 1; pp. 19 - 24
• Main Authors: YOON, Sorah, LEE, Garam, HAN, Dongun, SONG, Jae-Young, KANG, Kyung-Sun, LEE, Yong-Soon
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier 01.10.2010
• Subjects: Animals; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiviral agents; Antiviral Agents - pharmacology; Aptamers, Nucleotide - metabolism; Aptamers, Nucleotide - pharmacology; Aptamers, Nucleotide - therapeutic use; Biological and medical sciences; Capsid - drug effects; Capsid Proteins - genetics; Capsid Proteins - metabolism; Cell Line; Circovirus - drug effects; Circovirus - genetics; Circovirus - physiology; Fluorescent Antibody Technique, Indirect; Gene Expression; Medical sciences; Pharmacology. Drug treatments; Polymerase Chain Reaction; Pyrimidines; Recombinant Proteins; RNA; Sequence Analysis, DNA; Swine; Virulence - drug effects; Virus Replication - drug effects; RNA; Porcine circovirus; PCV2; Virus; Therapeutic agents; 2'F RNA aptamer; Circovirus; Infectivity; Antiviral; Aptamer; Circoviridae; Infected cell; Capsid; Mechanism of action; Veterinary; Neutralization
• DOI: 10.1016/j.antiviral.2010.06.012
• ISSN: 0166-3542

Porcine circovirus type 2 (PCV2) is the main causative agent of porcine circovirus-associated diseases (PCVD), which is responsible for economic losses in the swine industry. The capsid protein of PCV2 has important role for virus neutralization that blocks viral infection. To develop the therapeutic agents, two 2'F-RNA aptamers that bound to the PCV2 capsid protein with nanomole affinity were isolated from a 2'F-RNA library by the Systematic Evolution of Ligands by EXponential enrichment (SELEX). The binding affinity of aptamers was analyzed by Electrophoretic Mobility shift assay (EMSA) and surface plasmon resonance (SPR) analysis. The RNA aptamers have been shown to exhibit high affinity and specificity to PCV2 capsid protein and to neutralize PCV2 infectivity in PK-15 cells in dose dependent manner. Neutralizing aptamers such as this could be promising candidates in developing efficacious anti-PCV2 drugs as well as therapeutic delivery reagent.